An observational study in Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Syndrome, sponsored by Havva Betül Bacak. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-06.
Sponsored by Havva Betül Bacak · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Polycystic Ovary Syndrome with a site in Turkey — 14 open to participants now, 15 under way, none of them phase 3. Polycystic Ovary Syndrome · Turkey.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, this one is the 15th largest by planned enrollment of the 43 observational ones that give a count, is one of 7 that started in 2025, is one of 43 observational ones, reaches primary completion later than 2 of the 14 other live ones, and was the 50th registered.
959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.
Browse Polycystic Ovary Syndrome studies →14 of the 72 studies in Polycystic Ovary Syndrome with a site in Turkey are open now. Recruiting first, the newest first:
Atlas University · Sites in Turkey
Ages 18–45 · Women only
Istanbul Health and Technology University · Sites in Turkey
Ages 18–40 · Women only · Healthy volunteers
Dicle University · Sites in Turkey
Ages 20–40 · Women only
Ege University · Sites in Turkey
Ages 18–40 · Women only
Marmara University · Sites in Turkey
Ages 18+ · Women only
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 128 is close to the median of 118 across 223 observational studies indexed under Polycystic Ovary Syndrome.
Median enrollment 54 across the 29 interventional studies, 90 across the 43 observational. Of the 50 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 72 has an industry lead sponsor. The 10 most frequent:
Havva Betül Bacak is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Havva Betül Bacak has 1 study filed under Polycystic Ovary Syndrome — fewer than ten, so there is no comparison to draw.
7 of the studies in Polycystic Ovary Syndrome with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896642Istanbul Health and Technology UniversityBrown Adipose Tissue Modulation in Polycystic Ovary Syndrome Using Infrared Thermography | 2026-12 |
| NCT07509762Biruni UniversityExercise Programs in Women With PCOS | 2027-01-15 |
| NCT07871851Inonu UniversityInvestigation of the Effectiveness of Spinal Stabilization Exercises Added to Aerobic Exercise in Women With Polycystic Ovary Syndrome | 2027-01-20 |
| NCT07342946Atlas UniversityThe Effects of the Mediterranean Diet and Synbiotics in Polycystic Ovary Syndrome | 2027-04-01 |
| NCT07731373Kayseri City HospitalBiomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS) | 2027-04-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 72 studies in Polycystic Ovary Syndrome with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Purpose of the Study:
This study is being conducted to examine a protein called MG53 (also known as TRIM72) in women with polycystic ovary syndrome (PCOS). MG53 is involved in cell membrane repair and may play a role in insulin resistance, which is common in PCOS.
Study Procedures:
Women between 18 and 45 years of age will be invited to participate. The study population will include both women diagnosed with PCOS and healthy controls. A single blood sample (approximately 5 mL) will be collected from each participant. MG53 levels will be measured using an ELISA laboratory assay.
Significance of the Study:
Analysis of MG53 levels in relation to hormonal and metabolic markers may help determine whether MG53 is associated with insulin resistance and other characteristics of PCOS.
Background:
Polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age and is often associated with insulin resistance and metabolic disturbances. MG53 (TRIM72) is a membrane repair protein that has been shown in some experimental studies to affect insulin signaling and glucose metabolism.
Rationale:
Because insulin resistance is a key feature of PCOS, investigating MG53 levels in women with PCOS may provide new insights into the pathophysiology of the syndrome. Understanding whether MG53 is elevated and how it correlates with metabolic and hormonal parameters could lead to new diagnostic or therapeutic approaches in the future.
Study Design:
This is an observational, cross-sectional, single-center study. A total of 128 participants will be included: 64 women diagnosed with PCOS (based on the Rotterdam criteria) and 64 healthy women as controls.
Procedures:
Each participant will undergo a single blood draw (approximately 5 mL). MG53 levels will be measured using an ELISA method. Routine laboratory markers associated with PCOS (including HOMA-IR, BMI, LH/FSH ratio, total testosterone, DHEA-S, SHBG, free androgen index, triglycerides, HDL, LDL, and total cholesterol) will also be recorded from standard clinical evaluations.
Data Analysis:
Statistical analysis will include normality testing (Kolmogorov-Smirnov), comparison of groups (Student's t-test or Mann-Whitney U test), and correlation analyses (Pearson or Spearman). Sample size was calculated using G*Power software.
Outcome Measures:
The primary outcome is the serum level of MG53. Secondary outcomes include the correlation between MG53 levels and metabolic/hormonal parameters.
Significance:
This study does not involve any investigational drug or device and poses minimal risk to participants. The findings may contribute to the understanding of metabolic pathways involved in PCOS.
The study population consists of women aged 18 to 45 years. One group includes women diagnosed with polycystic ovary syndrome (PCOS) based on the Rotterdam criteria, and the other group includes healthy female controls without PCOS or other chronic conditions. All participants will provide informed consent before enrollment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Currently pregnant
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women aged 18-45 years diagnosed with polycystic ovary syndrome (PCOS) based on Rotterdam criteria. A single blood sample is collected for MG53 and routine metabolic markers. No intervention is applied.
Other: No intervention (observational study)
Women aged 18-45 years without PCOS or other chronic conditions. A single blood sample is collected for MG53 and routine metabolic markers. No intervention is applied.
Other: No intervention (observational study)
This is an observational study. No drugs, devices, or treatments are administered. Participants only provide a single blood sample for MG53 and routine metabolic measurements.
Serum MG53 level
Serum MG53 levels measured by ELISA in women with PCOS and healthy controls. Time Frame: At the time of blood draw (single measurement at enrollment)
Time frame: Baseline (single time point at enrollment)
Correlation between MG53 levels and insulin resistance (HOMA-IR)
Association between MG53 levels and HOMA-IR index derived from fasting glucose and insulin.
Time frame: At the time of blood draw (single measurement at enrollment)
Correlation between MG53 levels and BMI
Association between MG53 levels and body mass index (BMI).
Time frame: At the time of blood draw (single measurement at enrollment)
Correlation between MG53 levels and hormonal parameters
Association between MG53 levels and LH/FSH ratio, total testosterone, DHEA-S, SHBG, and free androgen index.
Time frame: At the time of blood draw (single measurement at enrollment)
Correlation between MG53 levels and lipid parameters
Association between MG53 levels and triglycerides, HDL-cholesterol, LDL-cholesterol, and total cholesterol.
Time frame: At the time of blood draw (single measurement at enrollment)
Plan to share: No — Individual participant data (IPD) will not be shared because this study does not include a plan for public data sharing, and participant consent for data sharing has not been obtained.
Started Jun 2025 (actual). Primary completion is estimated for Aug 2025, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Havva Betül Bacak